In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms

Author:

Abbas R1,Chow C P2,Browder N J1,Thacker D3,Bramer S L1,Fu C J4,Forbes W1,Odomi M5,Flockhart D A3

Affiliation:

1. Otsuka America Pharmaceutical, Inc., 2440 Research Boulevard, Rockville, Maryland, MD 20850, USA

2. Department of Drug Safety Evaluation, Purdue Pharma L.P. Ardsley, New York, NY 10502, USA

3. Department of Medicine, The Division of Clinical Pharmacology, Georgetown University Medical Center, Washington, DC, USA

4. Kansas City Analytical Services, Shawnee, Kansas, KS 66216, USA

5. Tokushima Research Institute, Otsuka Pharmaceutical Company, Tokushima, Japan

Abstract

1 Cilostazol (OPC-13013) undergoes extensive hepatic metabolism. The hydroxylation of the quinone moiety of cilostazol to OPC-13326 was the predominant route in all the liver preparations studies. The hydroxylation of the hexane moiety to OPC-13217 was the second most predominant route in vitro. 2 Ketoconazole (1 mM)wasthemostpotentinhibitorof both quinone and hexane hydroxylation. Both the CYP2D6 inhibitor quinidine (0.1 mM) and the CYP2C19 inhibitor omeprazole (10 mM) failed to consistently inhibit metabolism of cilostazol via either of these two predominant routes. 3 Data obtained from a bank of pre-characterized human liver microsomes demonstrated a stronger correlation (r2=0.68, P50.01) between metabolism of cilostazol to OPC-13326 and metabolism of felodipine, a CYP3A probe, that with probes for any other isoform. Cimetidine demonstrated concentration-dependent competitive inhibition of the metabolism of cilostazol by both routes. 4 Kinetic data demonstrated a Km value of 101 mM for cilostazol, suggesting a relatively low affinity of cilostazol for CYP3A. While recombinant CYP1A2, CYP2D6 and CYP2C19 were also able to catalyze formation of specific cilostazol metabolites, they did not appear to contribute significantly to cilostazol metabolism in whole human liver microsomes.

Publisher

SAGE Publications

Subject

Health, Toxicology and Mutagenesis,Toxicology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3